Checkpoint Therapeutics price target raised to $7 from $4 at Lake Street
Lake Street analyst Thomas Flaten raised the firm’s price target on Checkpoint Therapeutics (CKPT) to $7 from $4 and keeps a Buy rating on the ...
Checkpoint Therapeutics Upgraded to Buy Following FDA Approval and Increased Price Target
In a report released today, Thomas Flaten from Lake Street maintained a Buy rating on Checkpoint Therapeutics (CKPT – Research Report), with a ...